The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-FU, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: A trial of the Eastern Cooperative Oncology Group (E3204).
Steven J. Cohen
Honoraria - Genentech
Research Funding - Genentech
Yang Feng
No relevant relationships to disclose
Jerome Carl Landry
No relevant relationships to disclose
Charles A. Staley
No relevant relationships to disclose
Richard Whittington
No relevant relationships to disclose
Elin R. Sigurdson
No relevant relationships to disclose
Halla Sayed Nimeiri
No relevant relationships to disclose
Udit N. Verma
No relevant relationships to disclose
Al Bowen Benson
No relevant relationships to disclose